Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

Blocking the Mitochondrial pyruvate carrier and using aldose reductase inhibitors like Indian gooseberry and berberine may help with hair growth. Magnesium can also be added to increase NADPH.

People are eagerly awaiting the release of PP405, a new hair loss treatment. Some are using minoxidil and finasteride in the meantime, but there are concerns about scams and unverified products.

User starts Nuclear Stack treatment for hair loss, including Dutasteride, Minoxidil, RU58841, Derminator 2, and supplements. Seeks advice on storing and dosing RU58841.

Male pattern baldness (MPB) may be an early warning sign for type 2 diabetes due to its association with insulin resistance. Treatments discussed include testosterone therapy and finasteride, which affects hormone levels related to hair loss and insulin sensitivity.

A 19-year-old male with no family history of androgenetic alopecia (AGA) is experiencing hair loss and considering using a topical minoxidil and finasteride mixture. Despite low vitamin D levels and normal DHT serum levels, he seeks confirmation of AGA before starting treatment.

RU58841 in glycerin may cause less irritation than in PG form, but its effectiveness might be reduced. Users discuss the potential trade-off between irritation and efficacy.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

The user is using a hair loss regimen involving 2ddr applied twice daily, tretinoin weekly, and occasionally micro-needling. They report feeling increased scalp thickness and seeing some hair growth progress.

The user is seeking advice on sourcing finasteride, dutasteride, and minoxidil, as their doctors are unwilling to prescribe both finasteride/dutasteride and minoxidil simultaneously. They are also looking for sources of GHK-Cu and RU58841 in the USA, with suggestions including using services like Hims, ro.co, and Musely.

A potential baldness cure, possibly PP405, might be available before the release of GTA 6, which is delayed to 2026 or 2027. There is skepticism about the effectiveness and release timeline of PP405.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.

A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.

The conversation is about the timeline for Kintor's phase 3 trials for GT20029 and the potential release of the product in three years. It also mentions treatments like Minoxidil, finasteride, and RU58841.

The conversation is about finding a source to buy RU58841 in Germany, specifically looking for a PG-free option. Users suggest buying powder and mixing it themselves, with one user recommending a specific website.

The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.

The potential hair regrowth benefits of ASC-J9, a synthetic modified version of curcumin that is said to be more effective than Minoxidil and Finasteride. Reports from users suggest good thickening and temple regrowth with topical use at 0.025% concentration.

Using a combination of Stemoxydine, minoxidil, dutasteride, and keto shampoo to achieve extreme hair and beard growth. The user has experienced positive results with terminal hairs at the hairline and an increase in density to their stubble after several weeks of use.

The user has DUPA and suspects autoimmune activity as a cause. They have tried various treatments including finasteride, minoxidil, dutasteride, pyrilutamide, estrogel, hydrocortisone, and clobetasol, and are now seeking a long-term immunosuppressant.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

The conversation is about hair loss treatments, specifically the anticipation for the release of a new treatment, GT20029, by 2028. Users are discussing their experiences with current treatments like finasteride and dutasteride, and the potential of future treatments, including FAK inhibitors and verteporfin trials.

Gym and creatine can cause hair loss by increasing testosterone and androgenic activity. DHT blockers may help some, while others need androgen suppression with topical AA like RU or Pyri.

Creatine may affect hair loss by reducing PGE2 levels, which could influence hair growth. The discussion highlights the need for more research on this potential mechanism.

User "logart89" claims DUT 3 times a week is better than daily FIN for hair loss. Their routine includes DUT, topical DUT, stemoxydine and alfatradiol mix, 5% minoxidil with tretinoin, and weekly derma stamping.

Follicusan DP is discussed as a potential alternative to Minoxidil without side effects, but information is scarce. It is noted to be of German origin and details on its mechanism are limited.

The user is seeking an alternative solvent for pyrilutamide due to skin irritation from ethanol and propylene glycol. They experienced similar issues with topical minoxidil.

DUPA is considered more treatable than FAPD, as FAPD involves scarring that prevents hair regrowth. The user has started treatment with oral dutasteride and minoxidil, hoping for better results than previous treatments.

PP405's effectiveness in increasing hair density is questioned due to a small sample size, despite investment from Google Ventures. Users express skepticism and suggest waiting for more conclusive results.

Breezula's phase 3 results are expected soon, but its release is likely delayed until 2027 or 2028. The discussion highlights the need for more hair growth stimulants like AMP-303 and PP-405, as current treatments like Dutasteride effectively stop hair loss but don't regrow hair.